NEW BRUNSWICK, N.J., March 15 /PRNewswire/ -- The importance of specialty pharmaceuticals is rising to prominence. With no investment in basic research, specialty pharma companies in-license products to drive revenue growth or develop new indications or new formulations for current products. Big Pharma, typically reticent to take notice of anything other than blockbuster drug sales, are taking time to spin off relatively small-revenue or underperforming products to fledgling specialty start-ups. Once a sleepy sector in the public markets, specialty pharmaceuticals are now being covered by a growing number of stock analysts. More and more specialty pharmaceutical company business plans are showing up on the desks of VCs, and they are responding positively: the number of specialty pharmaceutical venture investments is growing at an enormous pace. The 2006 conference on specialty pharmaceuticals is an unprecedented opportunity for big pharma, biotech, specialty pharma, drug delivery companies & investment banks to learn, network and partner with their industry counterparts and access new information, announces Strategic Research Institute.
The agenda features the latest state of the industry discussions, which are in panel format:
- Specialty Pharma Awareness to Attract Big Pharma Portfolio Divestitures - Therapeutic Area Specialization: What Does the Future Hold and What are the Unmet Areas for Lucrative Opportunities? - Partnering in Specialty Pharma: A Novel & Profitable Business Model for the Pharmaceutical Industry - What Venture Capitalists Want in a Specialty Pharma Investment & How Long Will They Continue to Invest in Specialty Pharma? PARTICIPANTS INCLUDE: Abeille Pharmaceuticals, Inc. Actinium Pharmaceuticals A.M. Pappas & Associates Analytica International Biovail Pharmaceuticals, Inc. Bristol-Myers Squibb Daiichi Medical Research, Inc. Davidson, Davidson & Kappel, LLC Domain Associates, LLC Edwards Angell Palmer & Dodge LLP Elan Pharmaceuticals Endo Pharmaceuticals, Inc Integrium Javelin Pharmaceuticals King Pharmaceuticals, Inc. Millennium Pharmaceuticals Nektar Therapeutics Novartis Pharmaceuticals Corporation Patrin Pharma Penwest Pharmaceuticals Provectus Pharmaceuticals, Inc. Recombinant Capital, Inc. Supernus Pharmaceuticals, Inc. Synergy Advisors, LLC Techno Venture Management Wyeth
To register for the event, please visit http://www.srinstitute.com/cs385. REGISTER BY APRIL 4 TO RECEIVE $200 OFF!
To receive the full agenda in PDF, please contact Ed Drilon of Strategic Research Institute at edrilon@srinstitute.com or 212-967-0095, x233 (please include name and corporate affiliation).
Leverage our strong position in the specialty pharma sector to showcase your products and services to this high-level, targeted audience of executive decision makers. To inquire about sponsorship & exhibition opportunities, please contact Jon Liong at 212-967-0095 x243, jliong@srinstitute.com. LUNCHEON SPEAKING OPPORTUNITIES FOR BOTH DAYS REMAIN AVAILABLE.
To become a media partner, please contact Cheryl Kahan-Radhuber at ckahan-radhuber@srinstitute.com.
Strategic Research Institute
CONTACT: For sponsorship & exhibition opportunities: Jon Liong at+1-212-967-0095 x243, jliong@srinstitute.com, or to become a media partner:Cheryl Kahan-Radhuber, ckahan-radhuber@srinstitute.com, or for the fullagenda in PDF: Ed Drilon, +1-212-967-0095, x233, edrilon@srinstitute.com,all of Strategic Research Institute
